DOI: 10.7664/CHE20180515
Cost-Utility Analysis of Nilotinib Versus High-dose Imatinib for the Second-Line Treatment of Patients with Chronic Myeloid Leukemia
Abstract：Objective:Based on the data of clinical treatment costs in China,the cost-utility of Nilotinib and high-dose imatinib for the second-line treatment of chronic myeloid leukemia in China,and provided evidence for nilotinib being included in medical insurance drug directory.Methods:Based on nationwide medical insurance data of chronic myeloid leukemia,cost-effectiveness was analyzed by quality-adjusted life year(QALY).Results:Model predicted that compared to high-dose imatinib in 5-years second-line treatment,nilotinib cumulatively reduced hospitalization by 148 times,and hospitalization length was reduced by 2 661.9 days,and gained QALY of 170.7,as well as saved direct medical expenses of 5.97 million yuan.Conclusion:Nilotinib was an absolute advantage as a second-line treatment of CML.Medical insurance fund would be greatly saved in the payment for CML treatment if Nilotinib could be included in the China's medical insurance directory,
Keywords：chronic myeloid leukemiatyrosine kinase inhibitorresistance/intolerancecost-utility analysis
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 57-61 )